Glaxosmithkline | GSK - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Aurora Cannabis CAD 230K 1.88M 2026-03
Bausch Health Companies USD 402M 5M 2026-03
Bristol-Myers Squibb USD 407M 4M 2026-06
Canopy Growth CAD 12.31M 4.97M 2026-03
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Drreddys Laboratories INR 1.06B 113M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
GlaxoSmithKline GBP 121M 46M 2026-06
Glaxosmithkline GBP 192.73M 14.79M 2026-03
J&J USD 43M 25M 2026-03
Merck USD 525M 46M 2026-06
Novartis USD 462M 119M 2026-06
Pacira USD 3.62M 77K 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 667M 4M 2026-06
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 13.94M 2.52M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 287M 109M 2026-06
Supernus Pharmaceuticals USD 910K 278K 2023-06
Takeda JPY 63.85B 20.2B 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Zoetis USD 61M 1000K 2026-06